Exscientia Raises $510 million IPO
Exscientia has raised $510M in IPO funding led by Various, with participation from Various (IPO). first AI-designed drug in clinical trials. The funds will be used to Advance Centaur Chemist AI pipeline of 10+ clinical compounds.
IPO$510 millionTotal tracked $510 millionOxford, UK
What it does
first AI-designed drug in clinical trials.
Traction
Market Analysis, Forecast, Size, Trends and Insights The company is using its latest financing to scale, with the IPO round serving as the clearest current traction signal in the source bundle.
Trend impact
first AI-designed drug in clinical trials. As adoption in Healthcare & Life Sciences expands, focused products from Exscientia can pressure incumbents or broader platforms that do not address the same problem directly.
Funding history
- October 1, 2021 · IPO · $510 million · Various (IPO)
Products & services
- World Artificial Intelligence Drug Discovery - Market Analysis, capability
- Forecast, Size, Trends and Insights - IndexBox. World Artificial capability
- Intelligence Drug Discovery - Market Analysis, Forecast, Size, Trends capability
- Insights - IndexBox capability
- IndexBox Quotient Sciences advances AI-designed drug product into Phase capability